CATEGORIES

RedHill inks $6M deal with Kukbo for COVID-19 drug in South Korea

RedHill Biopharma has entered into an exclusive licence agreement with Kukbo Co., a South Korean corporation, for oral opaganib for the treatment of COVID-19, in South Korea.

Leveraging Academia-Industry Collabs to Scale-up S&T Innovations

Global challenges are too large to tackle in isolation. The creation of new shared value in public research through academic-industry collaborations are gaining momentum in innovations in the science, life science, biotechnology, and pharmaceutical industries.

Exploring the Possibilities of RNA Therapeutics

Fuelled by the successful utilisation of the mRNA COVID-19 vaccines, RNA therapeutics are expected to make larger strides in the near future. Let’s look at some of the drugs in late stage trials and the trends that will shape the RNA therapies landscape in 2022 and beyond:

Burden of Uncorrected Myopia on APAC Healthcare Systems

Uncorrected myopia remains the leading cause of distance vision impairment globally, and its rising prevalence could cost billions of dollars in lost productivity in the coming decades. A hallmark study by the Brien Holden Vision Institute (BHVI) in Australia predicts that by 2050, over half the world’s population or 52 per cent will be myopic. Moreover, management and control of myopia is a relatively new concept in many countries. Let’s explore what possible steps can be undertaken to address this affliction.

Bharat Biotech, Biofabri to develop and distribute novel TB vaccine

India-based Bharat Biotech has announced the partnership with Biofabri, a Spanish biopharmaceutical company, to join forces to develop, manufacture and market a new tuberculosis vaccine in more than 70 countries in Southeast Asia and subSaharan Africa.

Aussie Institute combines statins with Evolocumab to lower heart attacks

A novel new therapy has been found to reduce harmful plaque in arteries and change its composition so it is less likely to rupture and cause a heart attack, following a clinical trial led by the Victorian Heart Institute (VHI) at Monash University.

Women Special - Breaking Down Disparities

Women continue to sustain the quest to make a mark in the workplace and balance their personal life. Pandemic or not, woman power has not diminished one bit, and it shows in their exemplary achievements in India and the rest of the world. On the occasion of Women’s Day, BioSpectrum Asia salutes 20 inspiring leaders of the life sciences industry in the APAC region, for motivating others around them, breaking the glass ceiling and paving their own paths in 2021. These 20 women are powerhouses in their respective fields, inspiring not just their employees and the people around them, but other women and the next generation of women leaders.

Japan Discovers Host Immune-Dependent Novel Anti-Coronavirus Antibody

The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), in partnership with Shionogi & Co. in Japan, has successfully identified a novel antiviral antibody for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its variants, and closely associated coronavirus species.

“Our COVID-19 Vax Efficacy is Promising; Lyme disease & Chikungunya Shots in pipeline”

Headquartered in France, Valneva is an established European specialty vaccine company that has already commercialised the Japanese encephalitis vaccine IXIARO/ JESPECT and the oral cholera vaccine DUKORAL.

“We are expanding our capacity across Asia”

The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Germany, in 2021. To discuss the latest developments in the company following this acquisition, BioSpectrum spoke to Jean-Marc Cappia (J-MC), Head of Cell Line, Media & Testing Solutions, and Stefan Northoff(SN), Head of Product Development for Cell Culture Media, Cell Lines & Testing Solutions, both at Sartorius. Edited excerpts;

Hong Kong's Pluslife Biotech launches first handheld COVID-19 nucleic acid test

Pluslife Biotech, an enterprise based in the Greater Bay Area in Hong Kong, has launched the first handheld COVID-19 Nucleic Acid Test to help with epidemic prevention and control.

Psychedelic Trip to Wellness

Psychedelics have been used throughout history for medical purposes before being classified as illicit drugs in the 1960s. But that’s changing now, psychedelic drugs are gaining widespread attention as rigorous clinical trials have demonstrated their potential as a treatment for unmet needs in mental health. What explains this renaissance, how soon we will see psychedelic drugs in the market and most importantly where does big pharma stand in this? Let’s find out.

CEPI lays focus on developing heat-stable vaccine technology

Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has launched a new ‘Call for Proposals’ to improve the thermostability of vaccines against known epidemic and pandemic diseases like Ebola, Lassa fever, MERS, as well as COVID-19 or a novel Disease X.

A Reflection on 25 Years Well Spent: Building Our Reputation as Australia's Premier Bioanalytical and Toxicology Provider

This year, we at Agilex Biolabs celebrate our 25th year supporting Biotechs’ drug development programs as they champion safe and effective therapeutics through preclinical and clinical testing to bring relief to patient populations around the globe.

Boom Or Bust For Asian Healthcare?

Asia Pacific (APAC) is leaping with novel innovations while connecting the APAC market with global trends. Life sciences sector remains an attractive industry for investment from both strategic players and financial investors. The accelerated R&D activities amidst the pandemic attracted both outward direct investment (ODI) and foreign direct investment (FDI) in potential bio-pharma sectors at an estimated size of $40.25 billion in 2021. The surge in the pandemic is burgeoning consumer demand for innovative and potential healthcare products with the emerging digital health tech market. Thus, it’s essential to statistically analyse the perspective of the investment attractiveness in the APAC economy and translate it into a quantitative score to benchmark the performance of innovation and investments. Let’s gather some industry perspective on policy strengths and challenges in the markets for different stakeholders.

‘Click M' For Mental Health

Mental health and wellbeing has become a major cause for concern, especially due to the pandemic-induced psychological traumas, stemming from spending long hours in the confines of one’s home, minimal to zero social interaction, inability to meet and greet friends and family, as before and financial insecurity. Little wonder that the mental health space turned out to be ‘the hot’ sector in 2021, with funding more than doubling globally, climbing from $2.3 billion to $5.5 billion. As app-based mental health solutions are becoming a rage in APAC, we take a quick look at a few promising players.

US Highlights Covid-19 Neurological Symptoms

SARS-CoV-2 was initially identified as a respiratory virus, but it can affect the entire body, including the nervous system.

How IP Nitty-gritties Hinder Universal Immunisation

Since the COVID-19 immunisation started almost a year ago in January 2021, 60.2 per cent of the world population has received at least one dose of a COVID-19 vaccine and only 9.4 per cent of people in low-income countries have received at least one dose (source: our world in data). While there are many challenges to do so, the repeated argument being ‘pharma companies should forego Intellectual Property (IP) to expedite universal immunisation’. Should pharma companies waive IP during the pandemic? Will this ensure universal immunisation and equal distribution of therapies? Let’s find out.

Hong Kong develops anti-virus 3D printing material to rapidly terminate COVID-19

An interdisciplinary research team from The Hong Kong Polytechnic University (PolyU) has successfully developed the world’s first ‘anti-virus 3D printing material’ that can kill the COVID-19 virus on surfaces as well as most common viruses and bacteria.

Seeking The 'Fountain Of Youth'

In September 2021, Amazon founder Jeff Bezos invested in longevity biotech startup, Altos Labs putting the spotlight on the field of anti-ageing. Pharma and biotech firms are investing in research that could prevent and reverse the ageing process in humans, but can novel therapies actually provide longevity? Let's find out.

Hong Kong Studies Impact Of Pfizer Vaccine On Omicron Variant

A recent study jointly conducted by the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and the Faculty of Medicine, The Chinese University of Hong Kong (CU Medicine) has revealed that Omicron, the latest COVID-19 variant, can significantly reduce the virus neutralisation ability of Pfizer BioNTech (BNT162b2) vaccine by 32 folds or more. A similar test of another vaccine used in Hong Kong, CoronaVac, is being conducted and the results will soon be available.

Can Supply Chains Turn Pandemic-Proof?

The sudden and extreme impact on supplier/distributor network in light of the pandemic, forced policymakers and pharma companies to rethink about supply chains. Has the industry rose to the challenge and mitigated those issues while also ensuring the supply chain remains resilient to future disruptions? Let's find out.

Are Boosters Another Shot In The Dark?

Omicron and newer emerging variants have been portrayed as a cause of concern globally as several low and middle-income countries have not been able to immunise their citizens due to the shortage of COVID-19 vaccines. Notably, it was in the double-vaccinated South African individuals that the Omicron variant was first discovered. The COVID-19 Vaccines Global Access (COVAX) had promised two billion doses of COVID-19 vaccines by the end of 2021 to a total of 92 low-and middle-income countries that are eligible to receive COVID-19 vaccines through the COVAX mechanism. But, it has managed to deliver only about 95 million doses as developed nations hoarded surplus doses of the vaccines. Approximately 75 per cent of the 4.5 billion first doses of the COVID-19 vaccine that were rolled out, went to affluent countries. Can emerging variants make vaccine inequity a bigger challenge than it already is? Let's unravel.

Korea issues marketing authorisation to Moderna COVID-19 vaccine

American firm Moderna has announced that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorisation for Spikevax, Moderna's COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.

We want to work with global innovation leaders in disruptive technologies

A company's agile structure depends on creating a network of scientific advisors and venture partners to accelerate its innovations and potentials. To achieve this, venture capitalists assist healthcare and biopharmaceutical companies at all stages of development, be it company's early-stage designing, stimulating transformative technologies or nurturing business growth. Erning Cao, Investment Director at Evonik Venture Capital (Shanghai, China) shares insights on strategic venture capital investment towards innovative business models in APAC healthcare industry promoting sustainable and ethical practices in the region.

Gilead Sciences to help end HIV epidemic in APAC with $1.5 M grant

US-based Gilead Sciences has announced the recipients of its 2021 Gilead Asia Pacific (APAC) Rainbow Grant, a regional grant programme that supports community-led projects which place people living with HIV and their communities at the heart of care.

DIGITAL RESET

Nothing could have prepared the world for the unprecedented chain of events over the past two years. We prefaced 2020 and 2021 saying anything is possible, but no one saw this level of hyper volatility completely disrupting business and life as we know it. While the world is now firmly planted in a digital-format, the economic and business outlook for 2022 will remain highly fluid owing to the pandemic. Moreover, it is indeed very likely that in 2022, the majority of Asia Pacific's GDP will be coming from digital products, services, and experiences across industries, with life sciences being one of them.

CEPI funds project to develop COVID-19 vaccines for variants

Norway-based CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. in the US have announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other beta coronaviruses.

2022 seeks holistic revamping of pharma regulations

With the increasing relevance of the pharmaceutical industry, worldwide, as well as domestically, developments in regulation and policy pertaining to the industry are being keenly watched. We explore the expectations of a few opportunities and challenges that are projected for this industry in the coming year.

Who Covid-19 Solidarity Trial Picks Taiwan's Medigen's Vaccine

Taiwan’s Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation (WHO) Solidarity Trial Vaccines (STv).